|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, of 35 tumor cell lines surveyed, only 6 cell lines expressed HGF mRNA, and no HCC cell line expressed HGF.
|
1309612 |
1992 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Seven patients with HCC who underwent transcatheter arterial embolization (TAE) exhibited a gradual increase in serum HGF levels up to day 4 after treatment; these higher levels were maintained until day 7, although AST reached a peak on day 2 and then decreased gradually.(ABSTRACT TRUNCATED AT 250 WORDS)
|
7806142 |
1995 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus hepatocellular cancer tissue does not over-express mRNA for hepatocyte growth factor, though this growth factor might play a role in hyperproliferative states leading to liver cancer.
|
7989714 |
1994 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor (HGF) is an important paracrine regulator for liver growth, whereas it inhibits growth of tumor cells including hepatocellular carcinoma.
|
8179588 |
1994 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These findings suggest that hepatocyte growth factor may be involved in the regeneration of hepatocytes via paracrine mechanism in chronic active hepatitis, while in regulation of c-met expression in hepatocellular carcinoma tissues may be independent of hepatocyte growth factor stimulation.
|
8778194 |
1996 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical data correlated with PCR results regarding the overexpression of the HGF/c-met system in HCC.
|
9010472 |
1997 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Western blotting was used to examine the c-met expression, and HGF concentration in tumors was measured using an enzyme-linked immunosorbent assay. c-met was found to be overexpressed in HCC compared with nontumorous liver tissue (P < .01), and correlated with an increased incidence of intrahepatic metastases (P = .039).
|
9096589 |
1997 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
|
9815784 |
1997 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
4-[3,5-Bis(trimethylsilyl)benzamido] benzoic acid (TAC-101) inhibits the intrahepatic spread of hepatocellular carcinoma and prolongs the life-span of tumor-bearing animals.
|
9932610 |
1998 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of c-met mRNA and under-expression of HGF mRNA were detected in the HCCs compared with the corresponding peri-tumoral tissues.
|
10925356 |
2000 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study we show that the conditioned medium (CM) from the same HCC cell lines dose-dependently stimulates HGF secretion by myofibroblasts.
|
10995891 |
2000 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocellular carcinomas that had developed in non-cirrhotic livers contained essentially the same amount of hepatocyte growth factor as the matching non-tumoral liver.
|
11211911 |
2001 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The serum HGF levels tended to be higher in patients with LC and HCC than those with CH.
|
11223718 |
2001 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Two colon cancer cell lines (DLD and LoVo), a hepatocellular carcinoma cell line and a myelomonocytic cell line were incubated with LPS for 0-72 h, and transforming growth factor (TGF) beta1 and beta2, hepatocyte growth factor (HGF) and interleukins 6, 8 and 15 were assayed.
|
11725828 |
2002 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine.
|
11896611 |
2002 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
|
12619035 |
2003 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
|
12619035 |
2003 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: favouring role of hypoxia-inducible factor-1 deficiency.
|
12821940 |
2003 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The proapoptotic effect of HGF in c4 hepatocarcinoma cells seems to be related to HIF-1 deficiency with loss of cytoprotective and signalling functions.
|
12821940 |
2003 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Low hSulf1-expressing cells showed increased sulfation of cell-surface HSPGs, enhanced FGF and HGF-mediated signaling, and increased HCC cell growth.
|
14699503 |
2004 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that SU5416 inhibited motility scattering and the invasive activity of a hepatocellular carcinoma cell line HepG2 in vitro and growth in primary cultured hepatocytes induced by HGF.
|
15288476 |
2004 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Hepatocyte growth factor enhances protein phosphatase Cdc25A inhibitor compound 5-induced hepatoma cell growth inhibition via Akt-mediated MAPK pathway.
|
15534860 |
2005 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In vitro, transduction of HCC cell lines with the replication-deficient recombinant adenoviral vector AdCMV.NK4 resulted in significant inhibition of proliferation over and above the antimitogenic effects of HGF.
|
15905856 |
2005 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, adenoviral HGF gene transduction additively exerted inhibitory effects on cisplatin-treated hepatomas.
|
15942646 |
2005 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Twelve genes were significantly, differentially expressed in early HCCs compared with dysplastic nodules (>2-fold change; area under the receiver operating characteristic curve > or =0.8): this included TERT, GPC3, gankyrin, survivin, TOP2A, LYVE1, E-cadherin, IGFBP3, PDGFRA, TGFA, cyclin D1, and HGF.
|
17087938 |
2006 |